hVIVO plc (AIM:HVO)

Market Cap	55.11M -54.5%
Revenue (ttm)	54.47M -19.0%
Net Income	5.28M -69.7%
EPS	0.01 -69.5%
Shares Out	680.37M
PE Ratio	10.53
Forward PE	n/a
Dividend	0.00 (2.48%)
Ex-Dividend Date	May 15, 2025

Volume	1,355,525
Average Volume	4,733,967
Open	8.30
Previous Close	8.05
Day's Range	7.90 - 8.30
52-Week Range	4.31 - 19.50
Beta	1.60
RSI	50.40
Earnings Date	Apr 10, 2026

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Yamin Khan
• Employees: 301
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HVO

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.